Genetic Signatures for Distinguishing Chemo-Sensitive from Chemo-Resistant Responders in Prostate Cancer Patients

Area of Science:

• Oncology
• Molecular Biology
• Bioinformatics

Background:

• Prostate cancer poses a significant health challenge, especially in sub-Saharan Africa, with high mortality rates.
• Tumor heterogeneity complicates treatment, leading to variable patient responses and escalating chemotherapy resistance.
• Understanding the molecular basis of drug resistance is crucial for developing effective prostate cancer therapies.

Purpose of the Study:

• To investigate the expression of drug resistance-associated genes, ABCB1 and CYP1B1, in prostate cancer patient samples.
• To explore the molecular pathways and interactions associated with ABCB1 and CYP1B1 upregulation in the context of chemotherapy resistance.
• To analyze the molecular interactions between these genes and the chemotherapy drug docetaxel.

Main Methods:

• Quantitative PCR (qPCR) was used to analyze ABCB1 and CYP1B1 gene expression in pre-treatment biopsies from good and poor responders.
• Bioinformatic tools were employed for gene enrichment, network analysis, and STRING analysis to predict protein-protein interactions.
• Molecular docking simulations were performed to assess the binding interactions between docetaxel and the identified genes.

Main Results:

• Increased expression of ABCB1 and CYP1B1 was observed in tumor samples from poor responders compared to good responders.
• ABCB1 was associated with ABC transporters and LncRNA-mediated therapeutic resistance, while CYP1B1 was linked to steroidogenesis and metabolic pathways.
• Molecular docking revealed strong interactions between docetaxel and both ABCB1 and CYP1B1, indicating a potential mechanism for drug resistance.

Conclusions:

• Elevated ABCB1 and CYP1B1 expression in prostate tumors contributes to chemotherapy resistance by affecting associated molecular pathways.
• The identified molecular interactions between these genes and docetaxel provide insights into treatment failure.
• Targeting ABCB1 and CYP1B1 pathways may offer novel strategies for overcoming drug resistance in prostate cancer.